Organization to provide vaccinations & treatments for several monsoon related diseases and illnesses across all 102 clinics
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
The acquisition of LumiraDx’s Point of Care technology received all required antitrust and regulatory clearances
The revenue for the Q1FY25 came in at Rs 1,085.7 crore, up 16.6 per cent YoY
BAV has revolutionized the animal vaccination industry with its ground-breaking delivery methods that prioritize quality, safety, and efficacy
The inspection scope included 6 separate Biologics manufacturing units comprising 4 Drug Substance and 2 Drug Product manufacturing plants
Acquisition in line with Mankind’s stated objective to expand its presence in high entry barrier complex portfolios and high potential OTX brands
Giroctocogene fitelparvovec study meets primary and key secondary objectives of superiority compared to prophylaxis
A one-time dose of DURVEQTIX has reduced bleeds post-treatment compared to standard of care with a median annualized bleed rate (ABR) of zero bleeds (range 0 to 9.9)
The discussion at the fourth session was centered on the fusion of academic rigor and industrial pragmatism as a key to pioneering solutions for sustainable and prosperous future
Subscribe To Our Newsletter & Stay Updated
